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Th  e past decade has seen tremendous advances in the 
development of biomarkers for Alzheimer’s disease (AD), 
raising the question as to whether these markers are now 
ready to serve as a gold standard. Th  e  deﬁ  nitive diagnosis 
of AD currently requires pathologic conﬁ  rmation, but it 
is likely that several of the currently available biomarkers 
can add suﬃ   cient precision to the clinical diagnosis of 
AD dementia to approach a level of accuracy similar to 
autopsy diagnosis.
Elegant work by Cliﬀ   Jack and colleagues has suggested 
there is a dynamic temporal sequence of biomarkers that 
evolves over the course of AD, and thus the optimal set of 
biomarkers for diagnosis and/or tracking progression is 
probably dependent on the stage of AD [1]. Th  e  predic-
tive value of biomarkers early in this sequence is particu-
larly relevant to the widely acknowledged need to move 
therapeutic interventions earlier in the pathophysiologic 
process of AD for maximal eﬃ   cacy.  Broadly,  these 
biomarkers can be divided into three categories: evidence 
of amyloid-β deposition, detected by positron emission 
tomography (PET) amy  loid imaging or cerebrospinal 
ﬂ   uid (CSF) markers of Aβ; evidence of synaptic 
dysfunction, detected by [18F]ﬂ  uorodeoxyglucose-PET or 
functional magnetic resonance imaging (MRI); and evi-
dence of neuro  degenera  tion or neuronal loss, detected by 
CSF tau and atrophy detectable with volumetric MRI. We 
will brieﬂ   y review the utility of these biomarkers in 
clinical diagnosis and research criteria across the con-
tinuum from AD dementia back to cognitively normal 
older individuals who may be in presymptomatic stages 
of AD.
By the stage of AD dementia, there is clear evidence of 
abnormality in all biomarker categories, including low 
CSF Aβ and elevated CSF tau, increased PET amyloid 
tracer retention, [18F]ﬂ  uorodeoxyglucose hypometabolism, 
default network disruption on functional MRI, cortical 
thinning and hippocampal atrophy on volumetric MRI. It 
is widely acknowledged that a small percentage of 
clinically diagnosed AD patients do not meet autopsy 
criteria for AD – even in academic specialty clinics – 
and, similarly, a small proportion of clinically diagnosed 
AD patients do not show evidence of amyloid on either 
CSF or PET amyloid imaging markers. Although it is 
thought that these biomarker-negative dementia patients 
are probably misdiagnosed with AD, this remains to be 
proven with longitudinal follow-up and/or autopsy 
conﬁ  rmation.  Th  ere are a handful of case reports of 
patients with autopsy-conﬁ   rmed AD who had false-
negative PET amyloid imaging or CSF results, suggesting 
that there will probably never be perfect agreement. Th  e 
convergence of evidence thus far, however, suggests that, 
at the stage of clinical dementia, the absence of amyloid 
positivity should raise concern that a non-AD process is 
respon  sible for dementia.
At the stage of prodromal AD, biomarkers appear to be 
useful in characterizing the heterogeneous population of 
individuals under the general rubric of mild cognitive 
impairment (MCI). Autopsy studies suggest a substantial 
percentage of MCI subjects do not have evidence of AD 
pathology at autopsy [2], similar to the proportion of 
amyloid-negative MCI subjects in PET amyloid imaging 
series [3] (Figure 1). Both CSF and PET amyloid imaging 
markers have demonstrated positive predictive value for 
progres  sion to AD dementia within 2 to 3 years [3-5]. 
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provide complementary information in diagnostic 
accuracy and in prediction of cognitive decline [6], and it 
has been suggested that amnestic MCI plus Aβ depo-
sition and/or signiﬁ  cant atrophy may already represent 
early AD [7]. By the point of late MCI, amyloid deposition 
is thought to be well underway, perhaps already begin-
ning to plateau, and markers of downstream neuronal 
dysfunc  tion and neurodegeneration may be more useful 
in track  ing progression from late MCI into dementia [1].
Biomarkers may have particular utility in selecting 
appropriate patients for inclusion in clinical trials and for 
monitoring therapeutic response. As the majority of 
current therapeutic trials in MCI and mild AD are anti-
amyloid agents, it seems critical to test these drugs in 
individuals with amyloid pathology. Th   is is of particular 
importance in the heterogeneous MCI population, since 
inclusion of a signiﬁ  cant proportion of individuals with-
out amyloid pathology introduces noise into the clinical 
trial, and may expose individuals without the target 
pathology to needless risk. Th  e selection of a particular 
biomarker to monitor therapeutic response will probably 
depend on the speciﬁ  c drug mechanism of action and on 
the ability to correlate biomarker change with clinical 
response, but recent reports suggest that biomarkers can 
at least detect evidence of biological activity [8].
Biomarkers may ultimately prove most useful in 
identifying cognitively normal older individuals in the 
presymptomatic or preclinical stages of AD. Speciﬁ  cally, 
converging data suggest that amyloid accumulation 
begins years, perhaps at least a decade, prior to the onset 
of clinical impairment. Skeptics of the amyloid hypothesis 
have used the mismatch between pathological and 
clinical states as evidence against amyloid being the 
primary pathologic entity. Early evidence suggests, 
however, that the presence of either CSF or PET markers 
of amyloid pathology in clinically normal older 
individuals is asso  ciated with AD-like alterations on 
functional and structural imaging [9-11], increases in 
CSF tau [12], worse cognitive performance [13], and 
increased likelihood of cognitive decline and progression 
to early dementia [14]. Th  ere is, however, likely to be 
considerable variability in the emergence of clinical 
symptomatology due to other factors, such as cognitive 
reserve [13], or due to the presence of additional cerebral 
insults, such as cerebro  vascular disease [15].
At this point, it remains unknown whether the 
presence of amyloid pathology is both necessary and 
suﬃ     cient to predict the progression to clinical AD. 
Several longitudinal studies in older individuals charac-
terized by their amyloid status are ongoing, as well as 
studies in asymptomatic apolipoprotein E ε4 carriers and 
presymptomatic carriers of autosomal dominant muta-
tions, which should provide critical information regard-
ing the sequence of biomarkers in the preclinical stages 
of AD, and should serve to move the ﬁ  eld towards earlier 
diagnosis and therapeutic intervention. It is entirely 
possible that amyloid-modifying therapies will be maxi-
mally eﬃ   cacious prior to any cognitive impairment. Th  e 
analogy to cholesterol and cardiovascular and cerebro-
vascular disease may be particularly relevant here. 
Although there is clear evidence that lowering certain 
forms of cholesterol signiﬁ  cantly reduces the likelihood 
of myocardial infarction, there is little beneﬁ  t to reducing 
Figure 1. Amyloid deposition in cognitively normal elders, mild cognitive impairment and Alzheimer’s disease. (a) Representative 11C-PiB 
positron emission tomography images from a cognitively normal older individual (CN) without evidence of amyloid pathology (PiB–), from a 
normal older individual with elevated PiB retention indicating amyloid deposition (PiB+), and from a patient with mild Alzheimer’s disease (AD) 
with extensive amyloid deposition. (b) Scatterplot of PiB distribution volume ratio (DVR) for CN, mild cognitive impairment (MCI) and AD groups, 
demonstrating a subset of CN and MCI individuals with evidence of amyloid deposition in the range of AD patients.
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myopathy. If this is the case for early amyloid pathology 
and AD, we may need to rely solely on biomarkers to 
identify individuals in the presymptomatic stages of AD 
and to track their response to therapeutic intervention 
prior to the emergence of clinical symptomatology.
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